{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:44:00Z","timestamp":1785545040063,"version":"3.56.0"},"reference-count":30,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n The introduction of pneumococcal vaccination programs in the United Kingdom has led to substantial reduction in the burden of pneumococcal disease in the general population, decreasing the incidence of invasive pneumococcal disease and preventing associated mortality. Current UK guidelines recommend pneumococcal vaccination for adults aged \u226565 years, as well as for individuals aged \u22652 years with underlying medical conditions that place them at increased risk of severe pneumococcal disease. This includes adults with immunosuppression. To date, there are few data in the United Kingdom of pneumococcal vaccine coverage in specific high-risk groups, such as those with immunocompromised conditions.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n We aim to evaluate the yearly uptake of pneumococcal vaccine in adults who are included in national recommendations as people with immunosuppressive conditions, stratified by etiology of immunosuppression.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This will be a retrospective cohort study with data from the Oxford-Royal College of General Practitioners Research and Surveillance Centre network, which is nationally representative of the English population. The population under study includes adults registered in the Research and Surveillance Centre database with immunosuppression, including those with bone marrow compromise, with solid organ transplant, receiving oncological treatment, using immunosuppressive drugs, or with primary or acquired immunodeficiencies. The exposure is the underlying medical condition leading to an immunosuppression category. The primary outcome will be pneumococcal vaccination, defined as one dose of the 23-valent pneumococcal polysaccharide vaccine (PPV23).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study was funded in May 2025, and data extraction was performed from December 2025 to February 2026. Analysis was started in March 2026, with final results expected to be submited for publication in 2026. We will report pneumococcal vaccine uptake disaggregated for the high-risk group of people with immunosuppressive conditions, which has not been previously reported. We will also report on the socioeconomic gradient for vaccine uptake (through the use of the Index of Multiple Deprivation score and region) and report on the differences among ethnic groups.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n We will inform on the granularity of routine primary care data to include disaggregated reports of vaccine uptake in the immunosuppressed population in routine surveillance in the United Kingdom. This will aim to address the gap on pneumococcal vaccination coverage in people with immunosuppressive conditions, helping to identify potential unwarranted variations in vaccine adoption.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/92266","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T09:50:06Z","timestamp":1779616206000},"page":"e92266-e92266","source":"Crossref","is-referenced-by-count":0,"title":["Pneumococcal Vaccination Uptake in People With Immunosuppressed Conditions Using Real-World Primary Care Data Across England: Protocol for a Retrospective Descriptive Study"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6551-5484","authenticated-orcid":false,"given":"Bernardo","family":"Meza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9147-7784","authenticated-orcid":false,"given":"Gavin","family":"Jamie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8965-104X","authenticated-orcid":false,"given":"Jose","family":"Ord\u00f3\u00f1ez-Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4792-8995","authenticated-orcid":false,"given":"Rachel","family":"Byford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6982-3180","authenticated-orcid":false,"given":"Timea","family":"Suli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5425-3957","authenticated-orcid":false,"given":"Michael","family":"Bride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1365-843X","authenticated-orcid":false,"given":"Beno\u00eet","family":"Corriveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0631-6199","authenticated-orcid":false,"given":"Michael","family":"Feher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2897-2026","authenticated-orcid":false,"given":"Martin","family":"Whyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4974-3724","authenticated-orcid":false,"given":"Mark","family":"Joy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-2641","authenticated-orcid":false,"given":"Simon","family":"de Lusignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"5","key":"R1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/adc.2010.191718","article-title":"Invasive pneumococcal disease","volume":"96","author":"Randle","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"R2","unstructured":"UK Health Security Agency. Pneumococcal: the green book, chapter 25. GOV.UK. 2022. URL: https:\/\/www.gov.uk\/government\/publications\/pneumococcal-the-green-book-chapter-25 [Accessed 08-06-2026]"},{"key":"R3","unstructured":"Electronic Medicines Compendium (EMC). Pneumovax 23 solution for injection in pre-filled syringe. URL: https:\/\/www.medicines.org.uk\/emc\/product\/9692\/smpc [Accessed 18-01-2023]"},{"issue":"4","key":"R4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study","volume":"18","author":"Ladhani","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"R5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study","volume":"15","author":"Waight","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"R6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S1473-3099(23)00706-5","article-title":"Invasive pneumococcal disease 3 years after introduction of a reduced 1\u2009+\u20091 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study","volume":"24","author":"Bertran","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"R7","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3201\/eid2808.220304","article-title":"Increased incidence of invasive pneumococcal disease among children after COVID-19 pandemic, England","volume":"28","author":"Bertran","journal-title":"Emerg Infect Dis"},{"key":"R8","unstructured":"UK Health Security Agency. Influenza: the green book chapter. GOV.UK. 2025. URL: https:\/\/www.gov.uk\/government\/publications\/influenza-the-green-book-chapter-19 [Accessed 08-06-2026]"},{"key":"R9","unstructured":"UK Health Security Agency. COVID-19: the green book chapter. GOV.UK. 2025. URL: https:\/\/www.gov.uk\/government\/publications\/covid-19-the-green-book-chapter-14a [Accessed 08-06-2026]"},{"issue":"10","key":"R10","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jama.2023.28019","article-title":"Prevalence of immunosuppression among US adults","volume":"331","author":"Martinson","journal-title":"JAMA"},{"issue":"1","key":"R11","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03457-1","article-title":"Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England","volume":"22","author":"Chen","journal-title":"BMC Med"},{"key":"R12","unstructured":"UK Health Security Agency (UKHSA). Pneumococcal polysaccharide vaccine (PPV): vaccine coverage estimates. URL: https:\/\/www.gov.uk\/government\/publications\/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates [Accessed 03-06-2026]"},{"issue":"1","key":"R13","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-09613-5","article-title":"Pneumococcal vaccine coverage among individuals aged 18 to 64\u2009years old with underlying medical conditions in the UK: a retrospective database analysis","volume":"20","author":"Matthews","journal-title":"BMC Public Health"},{"issue":"3","key":"R14","doi-asserted-by":"publisher","DOI":"10.2196\/19773","article-title":"The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: protocol to develop extended COVID-19 surveillance and trial platforms","volume":"6","author":"de Lusignan","journal-title":"JMIR Public Health Surveill"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.2196\/39297","article-title":"A profile of influenza vaccine coverage for 2019-2020: a database study of the English primary care sentinel cohort","volume":"10","author":"Hoang","journal-title":"JMIR Public Health Surveill"},{"issue":"663","key":"R16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3399\/bjgp17X692645","article-title":"RCGP Research and Surveillance Centre: 50 years\u2019 surveillance of influenza, infections, and respiratory conditions","volume":"67","author":"de Lusignan","journal-title":"Br J Gen Pract"},{"issue":"4","key":"R17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011092","article-title":"Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile","volume":"6","author":"Correa","journal-title":"BMJ Open"},{"issue":"12","key":"R18","doi-asserted-by":"publisher","DOI":"10.2196\/39141","article-title":"Representativeness, vaccination uptake, and COVID-19 clinical outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: cohort profile summary","volume":"8","author":"Leston","journal-title":"JMIR Public Health Surveill"},{"issue":"10285","key":"R19","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","article-title":"Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study","volume":"397","author":"Vasileiou","journal-title":"The Lancet"},{"issue":"7","key":"R20","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"27","author":"Simpson","journal-title":"Nat Med"},{"issue":"4","key":"R21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jinf.2023.08.005","article-title":"COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study","volume":"87","author":"Whitaker","journal-title":"J Infect"},{"issue":"1","key":"R22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.14236\/jhi.v13i1.580","article-title":"Codes, classifications, terminologies and nomenclatures: definition, development and application in practice","volume":"13","author":"de Lusignan","journal-title":"Inform Prim Care"},{"issue":"5","key":"R23","doi-asserted-by":"publisher","first-page":"E107","DOI":"10.1503\/cmaj.190757","article-title":"Development and validation of the Cambridge Multimorbidity Score","volume":"192","author":"Payne","journal-title":"CMAJ"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Tsang RSM Joy M Whitaker H et al. Development and validation of a modified cambridge multimorbidity score for use with internationally recognized electronic health record clinical terms (SNOMED CT). Public and Global Health. Preprint posted online on 2022. [doi: 10.1101\/2022.03.02.22271765]","DOI":"10.1101\/2022.03.02.22271765"},{"key":"R25","unstructured":"R: A language and environment for statistical computing. 2013. URL: https:\/\/www.r-project.org\/ [Accessed 03-06-2026]"},{"issue":"6","key":"R26","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.semarthrit.2015.01.002","article-title":"Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus","volume":"44","author":"Lawson","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"R27","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-15939-7","article-title":"Pneumococcal vaccination coverage and adherence to recommended dosing schedules in adults: a repeated cross-sectional study of the INTEGO morbidity registry","volume":"23","author":"Janssens","journal-title":"BMC Public Health"},{"issue":"14","key":"R28","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1016\/j.vaccine.2021.02.061","article-title":"Role of social determinants of health in pneumococcal vaccination among high-risk adults","volume":"39","author":"Gatwood","journal-title":"Vaccine (Auckl)"},{"issue":"5","key":"R29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jnma.2019.04.011","article-title":"Racial disparities in adult pneumococcal vaccination indications and pneumococcal hospitalizations in the U.S","volume":"111","author":"Nowalk","journal-title":"J Natl Med Assoc"},{"issue":"7","key":"R30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/vaccines11071259","article-title":"A systematic review of behaviour change techniques within interventions to increase vaccine uptake among ethnic minority populations","volume":"11","author":"Ekezie","journal-title":"Vaccines (Basel)"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e92266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:23:58Z","timestamp":1785536638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e92266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":30,"URL":"https:\/\/doi.org\/10.2196\/92266","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"v15i5e92266"}}